Oppenheimer & Co. Inc. Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

Oppenheimer & Co. Inc. lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 91.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,976 shares of the medical device company’s stock after selling 32,684 shares during the period. Oppenheimer & Co. Inc.’s holdings in DexCom were worth $446,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Gradient Investments LLC purchased a new stake in shares of DexCom in the second quarter valued at about $25,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of DexCom during the second quarter worth $31,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of DexCom during the second quarter worth $37,000. Private Ocean LLC purchased a new position in DexCom in the 1st quarter valued at $36,000. Finally, Bremer Bank National Association purchased a new position in DexCom in the 1st quarter valued at $42,000. 96.79% of the stock is currently owned by institutional investors.

Shares of DexCom stock traded up $1.88 during trading on Wednesday, hitting $147.12. 10,005 shares of the company were exchanged, compared to its average volume of 895,107. DexCom, Inc. has a fifty-two week low of $105.05 and a fifty-two week high of $178.45. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56. The firm has a 50 day moving average price of $160.12 and a 200 day moving average price of $139.27. The stock has a market capitalization of $13.26 billion, a price-to-earnings ratio of 493.10 and a beta of 0.72.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.07. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The company had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. During the same period in the previous year, the firm posted ($0.10) earnings per share. The business’s revenue for the quarter was up 38.7% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 0.94 earnings per share for the current year.

A number of equities analysts have commented on DXCM shares. BMO Capital Markets upped their price objective on shares of DexCom from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. UBS Group lifted their price target on DexCom from $140.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. BTIG Research reaffirmed a “hold” rating on shares of DexCom in a report on Thursday, August 1st. Bank of America increased their price objective on DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Northland Securities reissued a “hold” rating and set a $125.00 price objective on shares of DexCom in a report on Thursday, June 6th. Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $168.44.

In related news, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $156.12, for a total value of $1,561,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Doubleday sold 2,016 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $175.14, for a total transaction of $353,082.24. Following the completion of the transaction, the executive vice president now owns 72,570 shares in the company, valued at $12,709,909.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,235 shares of company stock valued at $7,838,126. 0.88% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Penny Stocks

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.